Multiple Sclerosis: Other Treatments Under Study
Researchers continually search for new or better medicines to treat multiple sclerosis (MS). MS appears to be a disease in which the immune system attacks the covering of the nerves (myelin) within the brain and spinal cord. So treatments that reduce the activity of the immune system may slow the progression of the disease. Medicines that work in this manner are called immunosuppressants. They are a major focus of MS research.
Several immunosuppressants being studied or used for MS are:
- Azathioprine (Imuran), which has shown conflicting results but may reduce the number of relapses in relapsing-remitting MS.
- Cladribine (Leustatin), which has been used successfully against leukemia. The U.S. Food and Drug Administration (FDA) did not approve this drug for treatment of MS because of serious side effects, including death.
- Cyclophosphamide, which some experts believe stabilizes MS without improving it. But research has shown conflicting results.
- Methotrexate, which has also been used to treat cancer and rheumatoid arthritis. This drug may be of limited benefit in reducing the progression of MS.
- Monoclonal antibodies, such as:
- Alemtuzumab (Campath), which has been shown to reduce disability in relapsing-remitting MS. But the side effects of this medicine may include serious life-threatening complications.
- Daclizumab (Zenapax), which may reduce disease activity in relapsing-remitting MS.
- Rituximab (Rituxan), which has been shown to reduce the number of relapses in relapsing-remitting MS, but has had serious side effects, including PML.
- Laquinimod, which is still experimental. It has been shown to reduce the number of active lesions in people with MS, as seen on MRI.
Any therapy that can be used to treat MS must be judged by how it affects a person's degree of disability. Newer studies rely on the results of MRI scans and the progression of disability to evaluate how well therapy is working.
Other medicines being studied for multiple sclerosis (MS) include firategrast.
|Adam Husney, MD - Family Medicine|
|Barrie J. Hurwitz, MD - Neurology|
|Last Revised||May 9, 2013|
To learn more visit Healthwise.org